The pharmacologic and toxicologic evaluation of the ganglionic blocking agent, dibutadiamin.
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002415:Cats; D004285:Dogs; D005730:Ganglionic Blockers / Q000494:pharmacology* / Q000633:toxicity*; D005750:Gastric Juice; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006632:Histamine / Q000494:pharmacology; D008464:Mecamylamine / Q000494:pharmacology; D051379:Mice; D009132:Muscles / Q000187:drug effects*; D009469:Neuromuscular Junction / Q000187:drug effects*; D009541:Nictitating Membrane / Q000187:drug effects; D051381:Rats; D012018:Reflex; D012636:Secretory Rate; D013270:Stomach / Q000187:drug effects*; D013566:Sympathomimetics / Q000494:pharmacology; D013757:Tetraethylammonium Compounds / Q000494:pharmacology; D001743:Urinary Bladder / Q000187:drug effects*; D014666:Vasomotor System / Q000187:drug effects*
D005730:Ganglionic Blockers; D013566:Sympathomimetics; D013757:Tetraethylammonium Compounds; D000804:Angiotensin II; D008464:Mecamylamine; D006632:Histamine